ey0016.9-4 | Metabolic and Cardiovascular Risk in Cancer Survivors | ESPEYB16
IC Lega , JD Pole , PC Austin , C Lau , PC Nathan , NN Baxter
ey0016.15-7 | (1) | ESPEYB16
MR Perkin , HT Bahnson , K Logan , T Marrs , S Radulovic , J Craven , C Flohr , G Lack
ey0017.8-13 | New Concerns | ESPEYB17
Tang Rosalind , Howe Laura D , Suderman Matthew , Relton Caroline L , Crawford Andrew A , Houtepen Lotte C
ey0016.4-12 | New Paradigms | ESPEYB16
A Alisi , V Pampanini , C De Stefanis , N Panera , A Deodati , V Nobili , S Cianfarani
ey0015.7-13 | Secular trends and Turner syndrome | ESPEYB15
J Woelfle , A Lindberg , F Aydin , KK Ong , C Camacho-Hubner , B Gohlke
ey0020.8-1 | Clinical Trials – New Treatments | ESPEYB20
GP Forlenza , J McVean , RW Beck , C Bauza , R Bailey , B Buckingham , LA DiMeglio , JL Sherr , M Clements , A Neyman , C Evans-Molina , EK Sims , LH Messer , L Ekhlaspour , R McDonough , M Van Name , D Rojas , S Beasley , S DuBose , C Kollman , A Moran , CLVer Study Group
ey0017.8-2 | New Mechanisms | ESPEYB17
K Van Looveren , M Van Boxelaere , Z Callaerts-Vegh , C Libert
ey0018.11-5 | New hope: Increased diagnostic yield for disease causing MC4R variants and pharmacological treatment options | ESPEYB18
C Trier , M Hollensted , TM Schnurr , MAV Lund , TRH Nielsen , G Rui , EA Andersson , M Svendstrup , DS Bille , AP Gjesing , CE Fonvig , C Frithioff-Bojsoe , M Balslev-Harder , S Quan , M Gamborg , O Pedersen , L Angquist , JC Holm , T Hansen
ey0015.4-1 | Important for clinical practice | ESPEYB15
NE Bakker , A Lindberg , J Heissler , HA Wollmann , C Camacho-Hübner , AC Hokken-Koelega , on behalf of the KIGS Steering Committee
ey0018.10-8 | (1) | ESPEYB18
A Carlsson , M Shepherd , S Ellard , M Weedon , A Lernmark , G Forsander , K Colclough , Q Brahimi , C Valtonen-Andre , SA Ivarsson , H Elding Larsson , U Samuelsson , E Ortqvist , L Groop , J Ludvigsson , C Marcus , AT Hattersley